TY - JOUR AU - Dohner, H. AU - Estey, E. AU - Grimwade, D. AU - Amadori, S. AU - Appelbaum, F. R. AU - Buchner, T. PY - 2017 DA - 2017// TI - Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-08-733196 DO - 10.1182/blood-2016-08-733196 ID - Dohner2017 ER - TY - JOUR AU - Shaffer, B. C. AU - Gillet, J. P. AU - Patel, C. AU - Baer, M. R. AU - Bates, S. E. AU - Gottesman, M. M. PY - 2012 DA - 2012// TI - Drug resistance: still a daunting challenge to the successful treatment of AML JO - Drug Resist Updat VL - 15 UR - https://doi.org/10.1016/j.drup.2012.02.001 DO - 10.1016/j.drup.2012.02.001 ID - Shaffer2012 ER - TY - JOUR AU - Bhatla, T. AU - Wang, J. AU - Morrison, D. J. AU - Raetz, E. A. AU - Burke, M. J. AU - Brown, P. PY - 2012 DA - 2012// TI - Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia JO - Blood. VL - 119 UR - https://doi.org/10.1182/blood-2012-01-401687 DO - 10.1182/blood-2012-01-401687 ID - Bhatla2012 ER - TY - JOUR AU - Iwata, H. AU - Sato, H. AU - Suzuki, R. AU - Yamada, R. AU - Ichinomiya, S. AU - Yanagihara, M. PY - 2011 DA - 2011// TI - A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma JO - Int J Oncol VL - 38 ID - Iwata2011 ER - TY - JOUR AU - Mirza, S. AU - Sharma, G. AU - Pandya, P. AU - Ralhan, R. PY - 2010 DA - 2010// TI - Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents JO - Mol Cell Biochem VL - 342 UR - https://doi.org/10.1007/s11010-010-0473-y DO - 10.1007/s11010-010-0473-y ID - Mirza2010 ER - TY - JOUR AU - Mao, J. AU - Li, S. AU - Zhao, H. AU - Zhu, Y. AU - Hong, M. AU - Zhu, H. PY - 2018 DA - 2018// TI - Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines JO - Am J Transl Res VL - 10 ID - Mao2018 ER - TY - JOUR AU - Chen, L. AU - Mi, R. H. AU - Zhu, S. T. AU - Yu, P. AU - Wei, X. D. PY - 2018 DA - 2018// TI - Therapeutic effect of chidamide and decitabine in combiantion with CHAG priming regimen for 8 patients with relapsed/refractory acute myeloid leukemia JO - Zhonghua Xue Ye Xue Za Zhi VL - 39 ID - Chen2018 ER - TY - JOUR AU - Savickiene, J. AU - Treigyte, G. AU - Borutinskaite, V. V. AU - Navakauskiene, R. PY - 2012 DA - 2012// TI - Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells JO - Cell Mol Biol Lett VL - 17 UR - https://doi.org/10.2478/s11658-012-0024-5 DO - 10.2478/s11658-012-0024-5 ID - Savickiene2012 ER - TY - JOUR AU - Blagitko-Dorfs, N. AU - Schlosser, P. AU - Greve, G. AU - Pfeifer, D. AU - Meier, R. AU - Baude, A. PY - 2019 DA - 2019// TI - Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation JO - Leukemia. VL - 33 UR - https://doi.org/10.1038/s41375-018-0293-8 DO - 10.1038/s41375-018-0293-8 ID - Blagitko-Dorfs2019 ER - TY - JOUR AU - Huang, J. AU - Hong, M. AU - Zhu, Y. AU - Zhao, H. AU - Zhang, X. AU - Wu, Y. PY - 2018 DA - 2018// TI - Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia JO - Leuk Lymphoma VL - 59 UR - https://doi.org/10.1080/10428194.2018.1443328 DO - 10.1080/10428194.2018.1443328 ID - Huang2018 ER - TY - JOUR AU - Li, J. AU - Chen, Y. AU - Zhu, Y. AU - Zhou, J. AU - Xu, Y. AU - Li, Y. PY - 2015 DA - 2015// TI - Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.3361 DO - 10.18632/oncotarget.3361 ID - Li2015 ER - TY - JOUR AU - Qian, S. X. AU - Li, J. Y. AU - Tian, T. AU - Shen, Y. F. AU - Jiang, Y. Q. AU - Lu, H. PY - 2007 DA - 2007// TI - Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia JO - Leuk Res VL - 31 UR - https://doi.org/10.1016/j.leukres.2007.02.009 DO - 10.1016/j.leukres.2007.02.009 ID - Qian2007 ER - TY - JOUR AU - Pang, B. AU - Jong, J. AU - Qiao, X. AU - Wessels, L. F. AU - Neefjes, J. PY - 2015 DA - 2015// TI - Chemical profiling of the genome with anti-cancer drugs defines target specificities JO - Nat Chem Biol VL - 11 UR - https://doi.org/10.1038/nchembio.1811 DO - 10.1038/nchembio.1811 ID - Pang2015 ER - TY - JOUR AU - Pang, B. AU - Qiao, X. AU - Janssen, L. AU - Velds, A. AU - Groothuis, T. AU - Kerkhoven, R. PY - 2013 DA - 2013// TI - Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin JO - Nat Commun VL - 4 UR - https://doi.org/10.1038/ncomms2921 DO - 10.1038/ncomms2921 ID - Pang2013 ER - TY - JOUR AU - Roy, D. M. AU - Walsh, L. A. AU - Chan, T. A. PY - 2014 DA - 2014// TI - Driver mutations of cancer epigenomes JO - Protein Cell VL - 5 UR - https://doi.org/10.1007/s13238-014-0031-6 DO - 10.1007/s13238-014-0031-6 ID - Roy2014 ER - TY - STD TI - Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368: 2059-74. ID - ref16 ER - TY - JOUR AU - Metzeler, K. H. AU - Herold, T. AU - Rothenberg-Thurley, M. AU - Amler, S. AU - Sauerland, M. C. AU - Gorlich, D. PY - 2016 DA - 2016// TI - Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood-2016-01-693879 DO - 10.1182/blood-2016-01-693879 ID - Metzeler2016 ER - TY - JOUR AU - Uy, G. L. AU - Rettig, M. P. AU - Motabi, I. H. AU - McFarland, K. AU - Trinkaus, K. M. AU - Hladnik, L. M. PY - 2012 DA - 2012// TI - A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia JO - Blood. VL - 119 UR - https://doi.org/10.1182/blood-2011-10-383406 DO - 10.1182/blood-2011-10-383406 ID - Uy2012 ER - TY - JOUR AU - Roboz, G. J. AU - Rosenblat, T. AU - Arellano, M. AU - Gobbi, M. AU - Altman, J. K. AU - Montesinos, P. PY - 2014 DA - 2014// TI - International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.52.8562 DO - 10.1200/JCO.2013.52.8562 ID - Roboz2014 ER - TY - JOUR AU - Glass, J. L. AU - Hassane, D. AU - Wouters, B. J. AU - Kunimoto, H. AU - Avellino, R. AU - Garrett-Bakelman, F. E. PY - 2017 DA - 2017// TI - Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1032 DO - 10.1158/2159-8290.CD-16-1032 ID - Glass2017 ER - TY - JOUR AU - Maganti, H. B. AU - Jrade, H. AU - Cafariello, C. AU - Manias Rothberg, J. L. AU - Porter, C. J. AU - Yockell-Lelievre, J. PY - 2018 DA - 2018// TI - Targeting the MTF2-MDM2 axis sensitizes refractory acute myeloid leukemia to chemotherapy JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-17-0841 DO - 10.1158/2159-8290.CD-17-0841 ID - Maganti2018 ER - TY - JOUR AU - Welch, J. S. AU - Petti, A. A. AU - Miller, C. A. AU - Fronick, C. C. AU - O’Laughlin, M. AU - Fulton, R. S. PY - 2016 DA - 2016// TI - TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1605949 DO - 10.1056/NEJMoa1605949 ID - Welch2016 ER - TY - JOUR AU - Kadia, T. M. AU - Cortes, J. AU - Ravandi, F. AU - Jabbour, E. AU - Konopleva, M. AU - Benton, C. B. PY - 2018 DA - 2018// TI - Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial JO - Lancet Haematol VL - 5 UR - https://doi.org/10.1016/S2352-3026(18)30132-7 DO - 10.1016/S2352-3026(18)30132-7 ID - Kadia2018 ER - TY - JOUR AU - Ritchie, E. K. AU - Feldman, E. J. AU - Christos, P. J. AU - Rohan, S. D. AU - Lagassa, C. B. AU - Ippoliti, C. PY - 2013 DA - 2013// TI - Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia JO - Leuk Lymphoma VL - 54 UR - https://doi.org/10.3109/10428194.2012.762093 DO - 10.3109/10428194.2012.762093 ID - Ritchie2013 ER - TY - JOUR AU - Khan, N. AU - Hantel, A. AU - Knoebel, R. W. AU - Artz, A. AU - Larson, R. A. AU - Godley, L. A. PY - 2017 DA - 2017// TI - Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia JO - Leuk Lymphoma VL - 58 UR - https://doi.org/10.1080/10428194.2017.1289524 DO - 10.1080/10428194.2017.1289524 ID - Khan2017 ER - TY - JOUR AU - Momparler, R. L. AU - Idaghdour, Y. AU - Marquez, V. E. AU - Momparler, L. F. PY - 2012 DA - 2012// TI - Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation JO - Leuk Res VL - 36 UR - https://doi.org/10.1016/j.leukres.2012.03.001 DO - 10.1016/j.leukres.2012.03.001 ID - Momparler2012 ER - TY - JOUR AU - Nishioka, C. AU - Ikezoe, T. AU - Yang, J. AU - Udaka, K. AU - Yokoyama, A. PY - 2011 DA - 2011// TI - Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells JO - Leuk Res VL - 35 UR - https://doi.org/10.1016/j.leukres.2011.04.004 DO - 10.1016/j.leukres.2011.04.004 ID - Nishioka2011 ER - TY - JOUR AU - Kirschbaum, M. AU - Gojo, I. AU - Goldberg, S. L. AU - Bredeson, C. AU - Kujawski, L. A. AU - Yang, A. PY - 2014 DA - 2014// TI - A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome JO - Br J Haematol VL - 167 UR - https://doi.org/10.1111/bjh.13016 DO - 10.1111/bjh.13016 ID - Kirschbaum2014 ER - TY - JOUR AU - Tan, P. AU - Wei, A. AU - Mithraprabhu, S. AU - Cummings, N. AU - Liu, H. B. AU - Perugini, M. PY - 2014 DA - 2014// TI - Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome JO - Blood Cancer J VL - 4 UR - https://doi.org/10.1038/bcj.2013.68 DO - 10.1038/bcj.2013.68 ID - Tan2014 ER - TY - JOUR AU - Halpern, A. B. AU - Othus, M. AU - Huebner, E. M. AU - Buckley, S. A. AU - Pogosova-Agadjanyan, E. L. AU - Orlowski, K. F. PY - 2017 DA - 2017// TI - Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study JO - Leukemia. VL - 31 UR - https://doi.org/10.1038/leu.2017.165 DO - 10.1038/leu.2017.165 ID - Halpern2017 ER - TY - JOUR AU - Li, Y. AU - Wang, Y. AU - Zhou, Y. AU - Li, J. AU - Chen, K. AU - Zhang, L. PY - 2017 DA - 2017// TI - Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells JO - Clin Epigenetics VL - 9 UR - https://doi.org/10.1186/s13148-017-0377-8 DO - 10.1186/s13148-017-0377-8 ID - Li2017 ER - TY - JOUR AU - Chevallier, P. AU - Labopin, M. AU - Turlure, P. AU - Prebet, T. AU - Pigneux, A. AU - Hunault, M. PY - 2011 DA - 2011// TI - A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study JO - Leukemia. VL - 25 UR - https://doi.org/10.1038/leu.2011.25 DO - 10.1038/leu.2011.25 ID - Chevallier2011 ER - TY - JOUR AU - Cheson, B. D. AU - Bennett, J. M. AU - Kopecky, K. J. AU - Buchner, T. AU - Willman, C. L. AU - Estey, E. H. PY - 2003 DA - 2003// TI - Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.04.036 DO - 10.1200/JCO.2003.04.036 ID - Cheson2003 ER - TY - JOUR AU - Oken, M. M. AU - Creech, R. H. AU - Tormey, D. C. AU - Horton, J. AU - Davis, T. E. AU - McFadden, E. T. PY - 1982 DA - 1982// TI - Toxicity and response criteria of the Eastern Cooperative Oncology Group JO - Am J Clin Oncol VL - 5 UR - https://doi.org/10.1097/00000421-198212000-00014 DO - 10.1097/00000421-198212000-00014 ID - Oken1982 ER -